Bayer and Evotec join hands to develop new treatments for kidney diseases
Bayer and German firm Evotec have partnered to develop to new treatments for kidney diseases.
Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients.
Both parties will contribute novel drug targets and a set of technology platforms, and will share responsibilities during preclinical development.
Click on this link for more information.